LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News NEWS FLASH L impact Sep 30, 2026, 04:12 AM UTC

Poland: Rzeszów And Lublin Airports Temporarily Closed Due To Military Aviation Operations

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

Takeda Pharmaceutical Company Limited Reports Phase 3 Superiority of Zasocitinib vs Deucravacitinib Takeda reported Phase 3 head-to-head data showing zasocitinib achieved statistical superiority over deucravacitinib across primary and key secondary endpoints in moderate-to-severe L impact | NEWS | Sep 30, 2026, 05:00 AM UTC Cantargia AB (publ) (CANTA) Preclinical Data Back Nadunolimab+RASi, Phase 1b/2a Planned Cantargia reported preclinical data from Fred Hutch showing nadunolimab plus a RAS inhibitor reduced tumor burden and immune suppression in PDAC models, supporting a planned Phase L impact | NEWS | Sep 30, 2026, 05:00 AM UTC Roche launches newborn screening test for three severe genetic conditions BERLIN, Sept. 30, 2026 // -- Roche (SIX:RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB L impact | NEWS | Sep 30, 2026, 05:00 AM UTC Lonza Nominates Pearl Huang as Independent Board Member L impact | NEWS | Sep 30, 2026, 05:00 AM UTC Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and pote L impact | NEWS | Sep 30, 2026, 05:00 AM UTC Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026 L impact | NEWS | Sep 30, 2026, 05:00 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.